Substance misuse has a strict relationship with sexual dysfunctions. Psychoactive substances differently affect sexual performances in both sexes, and specific drugs and natural products are often chosen by males and females to enhance their experience and feelings before/during sexual encounters. Moreover, long-term drug users may suffer low libido, erectile dysfunction, and other sexual debilities due to the chronic effects of psychoactives on their body. A further theme of interest for mental health service workers is the intentional practice of sex under the influence of psychoactive substances, known as “chemsex,” and acted mainly among homosexual males. All these issues will be discussed in this chapter.
This is a preview of subscription content, access via your institution.
Nair R, Sellaturay S, Sriprasad S. The history of ginseng in the management of erectile dysfunction in ancient China (3500-2600 BCE). Indian J Urol. 2012;28:15–20.
Evans-Brown M, McVeigh J, Perkins C, Bellis M. Human enhancement drugs. The emerging challenges to public health. Liverpool: John Moore; 2012.
Jiann B. Erectile dysfunction associated with psychoactive substances. Chonnam Med J. 2008;44(3):117–24.
Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, et al. Sex, drugs, and rock “N” roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs [Internet]. 2012;44(1):38–55. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958/.
Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14):5274–8.
Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506–33.
Bradley KC, Boulware MB, Jiang H, Doerge RW, Meisel RL, Mermelstein PG. Changes in gene expression within the nucleus accumbens and striatum following sexual experience. Genes Brain Behav. 2005;4(1):31–44.
McCall H, Adams N, Mason D, Willis J. What is chemsex and why does it matter? BMJ [Internet]. 2015;351:h5790. http://www.bmj.com/lookup/doi/10.1136/bmj.h5790.
Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Schifano F, et al. Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and ginkgo biloba. Biomed Res Int. 2014;2014:13.
Pratap SA, Rajender S. Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities. Front Biosci (Schol Ed). 2012;4:167–80.
Kenyon SL, Button J, Perella P, McKeown DA, Holt DW. An herbal remedy for impotence: more than was bargained for. J Clin Pharmacol. 2006;46:1379–81.
Gonzales GF. Ethnobiology and ethnopharmacology of lepidium meyenii (Maca), a plant from the Peruvian Highlands. Evid Based Complement Alternat Med. 2012;2012:10.
Zheng BL, He K, Kim CH, Rogers L, Shao Y, Huang ZY, et al. Effect of a lipidic extract from lepidium meyenii on sexual behavior in mice and rats. Urology. 2000;55(4):598–602.
Cicero AFG, Piacente S, Plaza A, Sala E, Arletti R, Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia. 2002;34(3):177–9.
Lee MS, Shin B-C, Yang EJ, Lim H-J, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas. 2011;70(3):227–33.
Shin B-C, Lee MS, Yang EJ, Lim H-S, Ernst E. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med. 2010;10:44.
Piacente S, Carbone V, Plaza A, Zampelli A, Pizza C. Investigation of the tuber constituents of maca (Lepidium meyenii Walp.). J Agric Food Chem. 2002;50(20):5621–5.
Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med. 1985;14(10):1002–4.
Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California poison control system reported cases. Ann Pharmacother. 2010;44(6):1022–9.
Gass JT, Olive MF. Reinstatement of ethanol-seeking behavior following intravenous self-administration in Wistar rats. Alcohol Clin Exp Res. 2007;31(9):1441–5.
Feltenstein MW, See RE. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res. 2006;174(1):1–8.
Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry. 2002;51(8):642–51.
Greenwald MK, Lundahl LH, Steinmiller CL. Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals. Psychopharmacology. 2013;225:811–24.
Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010;11(2):171–81.
Kumar S, Madaan R, Sharma A. Pharmacological evaluation of bioactive principle of Turnera aphrodisiaca. Indian J Pharm Sci. 2008;70(6):740–4.
Arletti R, Benelli A, Cavazzuti E, Scarpetta G, Bertolini A. Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology. 1999;143(1):15–9.
Santacroce R, Corazza O, Martinotti G, Bersani FS, Valeriani G, Di Giannantonio M. Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum Psychopharmacol Clin Exp [Internet]. 2015;30(4):265–71. https://doi.org/10.1002/hup.2410.
Martinotti G, Lupi M, Carlucci L, Cinosi E, Santacroce R, Acciavatti T, et al. Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas. Hum Psychopharmacol. 2015;30(4):295–301.
Emboden WA. Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual. J Ethnopharmacol. 1981;3(1):39–83.
Fiorino DF, Phillips a G. Facilitation of sexual behavior in male rats following d-amphetamine-induced behavioral sensitization. Psychopharmacology. 1999;142(2):200–8.
Semple SJ, Patterson TL, Grant I. The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav. 2004;29(4):807–10.
Palha AP, Esteves M. Drugs of abuse and sexual functioning. Adv Psychosom Med. 2008;29:131–49.
Degenhardt L, Topp L. “Crystal meth” use among polydrug users in Sydney’s dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy. 2003;14:17–24.
Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abus Treat. 2002;22(2):103–8.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7:113–39.
Kobayashi H, Ujike H, Iwata N, Inada T, Yamada M, Sekine Y, et al. Association analysis of the tryptophan hydroxylase 2 gene polymorphisms in patients with methamphetamine dependence/psychosis. Curr Neuropharmacol. 2011;9:176–82.
Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33(3):223–32.
Gourley M. A subcultural study of recreational ecstasy use. J Sociol. 2004;40(1):59–73.
NIH. HSDB: 3,4-Methylenedioxymethamphetamine [Internet]. US National Library of Medicine. 2008 [cited 2017 Jan 20]. https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+42542-10-9.
Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) [Internet]. 1986;88(4):525–6. https://doi.org/10.1007/BF00178519.
Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.
McElrath K. MDMA and sexual behavior: ecstasy users’ perceptions about sexuality and sexual risk. Subst Use Misuse. 2005;6084:1461–77.
Zemishlany Z, Aizenberg D, Weizman A. Subjective effects of MDMA (“ecstasy”) on human sexual function. Eur Psychiatry. 2001;16(2):127–30.
Breslau K. The “sextasy” craze. Clubland’s dangerous party mix: Viagra and ecstasy. Newsweek. 2002;139:30.
Tran QT, Wallace RA, Sim EHA. Priapism, ecstasy, and marijuana: is there a connection? Adv Urol. 2008;2008:193694.
Romanelli F, Smith KM, Thornton AC, Pomeroy C. Poppers: epidemiology and clinical management of inhaled nitrite abuse. Pharmacotherapy. 2004;24(1):69–78.
Lampinen TM, Mattheis K, Chan K, Hogg RS. Nitrite inhalant use among young gay and bisexual men in Vancouver during a period of increasing HIV incidence. BMC Public Health. 2007;7:35.
Gruener AM, Jeffries MAR, El Housseini Z, Whitefield L. Poppers maculopathy. Lancet. 2014;384(9954):1606.
Romanelli F, Smith KM. Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. Ann Pharmacother [Internet]. 2004;38(6):1024–30. https://doi.org/10.1345/aph.1D571.
Stalnikowicz R, Amitai Y, Bentur Y. Aphrodisiac drug-induced Hemolysis. J Toxicol Clin Toxicol [Internet]. 2004;42(3):313–6. https://doi.org/10.1081/CLT-120037435.
Hagan IG, Burney K. Radiology of recreational drug abuse. RadioGraphics [Internet]. 2007;27(4):919–40. https://doi.org/10.1148/rg.274065103.
Grover S, Mattoo SK, Pendharkar S, Kandappan V. Sexual dysfunction in patients with alcohol and opioid dependence. Indian J Psychol Med. 2014;36:355–65.
Alcohol use and sexual risk behaviour: a cross-cultural study in eight countries. Geneva: World Health Organization; 2005. p. 148.
Arackal BS, Benegal V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J Psychiatry [Internet]. 2007;49(2):109–12. http://www.ncbi.nlm.nih.gov/pubmed/20711392.
Zaazaa A, Bella AJ, Shamloul R. Drug addiction and sexual dysfunction. Endocrinol Metab Clin N Am. 2013;42(3):585–92.
Amoako AA, Marczylo TH, Marczylo EL, Elson J, Willets JM, Taylor AH, et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod. 2013;28(8):2058–66.
Aversa A, Rossi F, Francomano D, Bruzziches R, Bertone C, Santiemma V, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int J Impot Res. 2008;20(6):566–73.
Pake JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manag. 1994;9(2):126–31.
Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings (‘chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect [Internet]. 2015;91(8):564–8. http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=CitingArticles&qid=1&SID=W1HnFq71TOmNoSHorBF&page=1&doc=1&cacheurlFromRightClick=no.
Race K. “Party ‘n’ play”: online hook-up devices and the emergence of PNP practices among gay men. Sexualities. 2015:1–40.
Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardo FP. When “chems” meet sex: a rising phenomenon called “ChemSex”. Curr Neuropharmacol. 2016;15(5):762–70.
Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15–26.
Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ. 2010;340:c1605.
Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am. 2014;32(1):1–28.
Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephedrone (4-methylmethcathinone; “meow meow”): chemical, pharmacological and clinical issues. Psychopharmacology. 2011;214(3):593–602.
Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J. 2011;28(4):280–2.
Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, “meow meow”) in the United Kingdom. J Clin Psychopharmacol. 2012;32(5):710–4.
Emcdda. Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone) In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances. EMCDDA Risk Assessments. 2011.
Newcombe R. Mephedrone: the use of mephedrone (M-cat, Meow) in Middlesbrough. Manchester: Lifeline Publications and Research; 2009. p. 1–16.
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol [Internet]. 2012;50(6):458–70. https://doi.org/10.3109/15563650.2012.702218.
Vickers MD. Gamma hydroxybutyric acid. Clinical pharmacology and current status. Proc R Soc Med [Internet]. 1968;61(8):821–4. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1902450&tool=pmcentrez&rendertype=abstract.
Sumnall HR, Beynon CM, Conchie SM, Riley SCE, Cole JC. An investigation of the subjective experiences of sex after alcohol or drug intoxication. J Psychopharmacol [Internet]. 2007;21(5):525–37. https://doi.org/10.1177/0269881106075590.
Brewster VL, Edwards HGM, Hargreaves MD, Munshi T. Identification of the date-rape drug GHB and its precursor GBL by Raman spectroscopy. Drug Test Anal. 2009;1(1):25–31.
Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs. 2007;39:115–29.
Abdulrahim D, Bowden-Jones O. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. 2015. 335 p. http://www.drugsandalcohol.ie/24292/.
Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD, BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52–78.
Hockenhull J, Murphy KG, Paterson S. An observed rise in γ-hydroxybutyrate-associated deaths in London: evidence to suggest a possible link with concomitant rise in chemsex. Forensic Sci Int [Internet]. 2017;270:93–7. https://doi.org/10.1016/j.forsciint.2016.11.039.
Editors and Affiliations
Rights and permissions
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Martinotti, G., Belfiglio, E., Santacroce, R., di Giannantonio, M. (2018). Sexual Dysfunctions and Substance-Related and Addictive Disorders. In: Jannini, E., Siracusano, A. (eds) Sexual Dysfunctions in Mentally Ill Patients. Trends in Andrology and Sexual Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-68306-5_14
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68305-8
Online ISBN: 978-3-319-68306-5
eBook Packages: MedicineMedicine (R0)